Article info
PDFCurrent controversy
Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
- Correspondence to Professor Søren Holm, CSEP, Department of Law, School of Social Sciences, The University of Manchester, Manchester M13 9PL, UK; soren.holm{at}manchester.ac.uk
Citation
Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
Publication history
- Received May 19, 2020
- Revised June 15, 2020
- Accepted June 18, 2020
- First published July 2, 2020.
Online issue publication
August 26, 2020
Article Versions
- Previous version (26 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Other content recommended for you
- Exploring the ethics of tuberculosis human challenge models
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Research ethics and public trust in vaccines: the case of COVID-19 challenge trials
- Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
- Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines
- Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study
- SARS-CoV-2 challenge studies: ethics and risk minimisation
- Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
- Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
- Review of COVID-19 vaccine subtypes, efficacy and geographical distributions